Clinical Trials Browser

Phase 1/2 × Neoplasms by Histologic Type × Gynecologic × Clear all

Mesothelioma, Malignant, Immune System Diseases, Immunoproliferative Disorders, Lymphatic Diseases, Lymphoma, Lymphoma, Non-Hodgkin, Lymphoproliferative Disorders, Neoplasms, Neoplasms by Histologic Type, Neoplasms by Site, Lymphoma, B-Cell, Lymphoma, T-Cell, Lymphoma, Large B-Cell, Diffuse, Endometrial Neoplasms, Prostatic Neoplasms, Castration-Resistant

NCT02759588 2023-01-05

GL-ONC1 Oncolytic Immunotherapy in Patients With Recurrent or Refractory Ovarian Cancer

Phase 1/2 Completed

46 enrolled

Gynecologic

Carcinoma, Fallopian Tube Neoplasms, Neoplasms, Neoplasms by Histologic Type, Neoplasms, Glandular and Epithelial, Ovarian Neoplasms, Peritoneal Neoplasms, Poxviridae Infections, Vaccinia, Virus Diseases

NCT00841191 2014-05-14

A Safety, Efficacy and Pharmacokinetic Study of Siltuximab (CNTO 328) in Participants With Solid Tumors

Phase 1/2 Completed

84 enrolled

GastrointestinalGynecologicHead & NeckThoracic

Head and Neck Neoplasms, Lung Neoplasms, Neoplasms by Histologic Type, Ovarian Neoplasms, Pancreatic Neoplasms, Colorectal Neoplasms

Clinical Trials

A Study of Tulmimetostat DZR123 (CPI-0209) in Patients With Advanced Solid Tumors and Lymphomas

GL-ONC1 Oncolytic Immunotherapy in Patients With Recurrent or Refractory Ovarian Cancer

A Safety, Efficacy and Pharmacokinetic Study of Siltuximab (CNTO 328) in Participants With Solid Tumors